유전체 편집 시장 : 채택된 결제 방법별, 유전자 편집 기술별, 유전자 편집 접근 방식별, 유전자 도입 방법별, 유전자 도입 모달리티별, 최종사용자별, 지역별, 주요 기업별 - 동향 및 예측(-2035년)

GENOME EDITING MARKET: OVERVIEW

As per Roots Analysis, the global genome editing market is estimated to grow from USD 5.29 billion in the current year to USD 13.36 billion by 2035, at an impressive CAGR of 10.8%, during the forecast period, till 2035.

Genome Editing Market: Growth and Trends

Genome editing refers to a set of genetic engineering techniques that allow researchers to insert, delete, or replace segments of DNA within the genome of an organism. Three broad classes of tools have emerged in gene editing over the past three decades namely, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the CRISPR-Cas system. Presently, CRISPR genome editing tool is widely used for gene editing owing to its precision, cost efficiency, and ease of design.

The clinical rationale for genome editing has strengthened significantly, driven by the substantial global burden of genetic disorders and the significant contribution of inherited genetic conditions to infant mortality. This disease burden, combined with maturing regulatory pathways for cell and gene therapies, has pushed genome editing from a research tool into a commercially viable therapeutic modality. Presently, over a thousand active clinical programs are currently evaluating gene-edited and gene-based interventions.

Pharmaceutical and biotechnology companies are increasingly licensing external editing platforms rather than building proprietary toolkits due to the high expense of in-house discovery and the regulatory complexity of gene-edited product development. This has created a distinct technology-licensing economy that sits at the center of the genome editing value chain and is a key structural feature distributors and channel partners should understand before entering this space.

Growth Drivers: Factors Fueling Expansion of the Global Genome Editing Market

Market growth is being driven by the steady clinical validation of CRISPR-based cell and gene therapies. Further, the expanding disease scope of genome editing beyond monogenic disorders into oncology, neurology and metabolic disease, and rising out-licensing activity among technology originators are the key drivers of the market. The transition toward next-generation base and prime editing tools, which offer more precise edits with fewer off-target effects, is widening the addressable therapeutic scope of the field. Growing agricultural and diagnostic applications of genome editing are reinforcing this trajectory outside of core therapeutics.

Market Challenges: Critical Barriers Hindering Progress

Despite strong momentum, the industry players are witnessing several challenges that impede market growth. In vivo genome editing remains limited by immunogenicity, off-target effects, and inadequate tissue specificity. On the other hand, ex vivo approaches are hindered by high costs and operational complexity. Additionally, fragmented CRISPR intellectual property and evolving regulatory frameworks continue to create licensing challenges and uncertainty around product approvals.

Genome Editing Market Segments

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Payment Method Employed

• Upfront Payments
• Milestone Payments

By Type of Gene Editing Technique

• CRISPR-Cas System
• TALENs
• Meganucleases
• ZFNs
• Other Techniques

By Gene Editing Approach

• Gene Knock-Out
• Gene Knock-In

By Type of Gene Delivery Method

• Ex Vivo
• In Vivo

By Gene Delivery Modality

• Viral Vectors
• Non-Viral Vectors

By Type of Therapy

• Cell Therapies
• Gene Therapies
• Other Therapies

By Application Area

• Drug Discovery and Development
• Diagnostics

By Type of End-User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes

By Geographical Regions

• North America
• US
• Canada
• Europe
• Germany
• France
• Ireland
• Asia-Pacific
• China
• Japan
• South Korea

Genome Editing Market: Key Segmentation Insights

By Payment Method

Upfront payments currently account for the largest share of the market. Capital commitment in the short term remains heavily weighted toward immediate technology acquisition and licensing rights to secure proprietary genome editing platforms. However, in the future, milestone-based payments segment is projected to hold the highest global market share by 2035 as licensing deals mature and more programs advance through clinical and commercial milestones.

By Gene Editing Technique

CRISPR-Cas systems dominate the technology landscape. This highest share is due to the versatility of the system and the emergence of refined variants such as base and prime editing that address earlier limitations around precision and off-target effects. Notably, this segment will continue to gain momentum, anticipated to register higher CAGR during the forecast period.

Market leadership is sustained by the platform's inherent versatility and rapid structural refinements. Next-generation tools specifically base editing and prime editing are mitigating early safety and accuracy challenges like off-target cleavage and double-stranded DNA breaks, solidifying CRISPR's position as the primary clinical standard.

By Gene Editing Approach

Gene knock-out approaches hold the largest share of the global market. This highest share is due to their relative technical simplicity compared with knock-in strategies, which require more complex optimization to achieve precise sequence insertion.

By Gene Delivery Method

Ex vivo delivery leads by holding highest share of the market. This dominance is largely because modifying cells outside the body allows tighter quality control and lower off-target risk than in vivo delivery. In ex vivo genome editing, patient-derived cells are isolated, genetically modified under controlled laboratory conditions, rigorously tested for editing efficiency and safety, and then reinfused into the patient.

This approach enables precise quality control, minimizes off-target editing, and reduces systemic exposure to genome editing components, thereby improving the overall safety profile. Furthermore, ex vivo delivery is well suited for CRISPR-Cas, TALEN, and zinc finger nuclease-based therapies targeting hematopoietic stem cells and immune cells, which have demonstrated encouraging clinical outcomes.

By Gene Delivery Modality

Viral vectors currently account for the largest share of the genome editing market, owing to their high gene transfer efficiency, robust transgene expression, and extensive clinical validation. Delivery platforms such as adeno-associated viruses (AAVs), lentiviral vectors, and adenoviral vectors are widely used in both clinical trials and approved gene and cell therapies, particularly for ex vivo applications. Their established manufacturing processes, well-characterized safety profiles, and regulatory familiarity have further strengthened their market position.

However, non-viral delivery modalities are expected to witness the fastest CAGR during the forecast period. This shift is driven by increasing demand for safer, more scalable, and cost-effective delivery platforms. Technologies such as lipid nanoparticles (LNPs), polymer-based nanoparticles, electroporation, and other physical delivery methods eliminate the risk of insertional mutagenesis, reduce immunogenicity, and enable repeat dosing, making them particularly attractive for in vivo genome editing applications.

.

By Type of Therapy

Cell therapies represent the leading application by holding the highest share. This highest share reflects their broad utility across multiple disease areas. Genome-edited cell therapies, particularly CAR-T, TCR-T, and hematopoietic stem cell-based therapies, have demonstrated significant clinical success and benefit from the use of ex vivo editing, which enables precise genetic modification, stringent quality control, and improved safety. The expanding pipeline of autologous and allogeneic cell therapies, coupled with increasing regulatory approvals, manufacturing investments, and strategic collaborations, continues to strengthen the segment's market leadership.

On the other hand, gene therapy, which is more narrowly focused on rare and monogenic conditions, is expected to grow at a higher CAGR during the forecast period. This growth is driven by the rapid advancement of CRISPR-based, base editing, prime editing, and mRNA-enabled genome editing technologies, which are expanding therapeutic opportunities beyond rare monogenic disorders to include more prevalent genetic, metabolic, ophthalmic, cardiovascular, and neurological diseases.

By Application Area

Drug discovery and development dominate the market. This highest share is driven by the use of CRISPR-based screening to identify novel drug targets. Conversely, diagnostic applications, while smaller today, are expected to expand at a higher CAGR during the forecast period as genome editing tools are adapted for early disease detection.

By End User

Pharmaceutical and biotechnology companies capture the highest share of the market, consistent with the fact that roughly 90% of technology licensing and integration agreements in this space are inked with commercial rather than academic entities.

North America Holds the Highest Share and Asia-Pacific Grows at Higher CAGR

According to our projections, North America leads the global market and is likely to remain dominant in the future. This growth is underpinned by the concentration of technology developers, the highest volume of licensing transactions and the largest pool of venture and institutional capital directed toward the sector.

Example Players in Genome Editing Market

• Arcturus Therapeutics
• ArsenalBio
• Avectas
• Beam Therapeutics
• Bio-Sourcing
• Caribou Biosciences
• Century Therapeutics
• CRISPR Therapeutics
• Editas Medicine
• Flash BioSolutions
• Graphite Bio
• Intellia Therapeutics
• NTrans Technologies
• OXGENE
• Prime Medicine
• Revvity
• Vor Biopharma

Expert Interview and Industry Insights

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Chief Executive Officer, Large Organization, US
• Chief Scientific Officer, Mid-Sized Organization, US
• Chief Technology Officer, Large Organization, Europe
• Vice President, Business Development, Large Organization, US
• Head of Research, Academic Institute, Asia-Pacific
• Chief Medical Officer, Mid-Sized Organization, US

GENOME EDITING MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: An in-depth analysis of the genome editing market size and forecast across key segments, including type of payment method employed, type of gene editing technique, gene editing approach, type of gene delivery method, gene delivery modality, type of therapy, application area, type of end-user and geography.
• Technology and Developer Landscape: A detailed assessment of the current technology landscape for genome editing, evaluated by type of gene editing technique, gene editing approach, gene delivery method, gene delivery modality, highest phase of development supported, therapeutic area and application area, along with an analysis of technology providers by year of establishment, company size, location of headquarters and operating model.
• Company Competitiveness Analysis: An insightful competitiveness analysis of genome editing technology providers, benchmarked on company strength and technology strength, segmented across peer groups headquartered in North America, Europe, and Asia-Pacific.
• Company Profiles: Elaborate and short profiles of prominent players developing genome editing technologies across North America, Europe and Asia-Pacific, featuring company overview, technology portfolio, recent developments, and an informed future outlook.
• Partnerships and Collaborations Analysis: A comprehensive assessment of partnership activity among genome editing technology providers since 2018, evaluated by year, type of partnership, focus area, geography, and most active players.
• Patent Analysis: An in-depth analysis of patents filed and granted to genome editing technology providers since 2018, evaluated by publication year, geography, CPC classification, and applicant type, along with patent benchmarking, valuation, and citation analysis.
• Funding and Investment Analysis: A comprehensive assessment of funding and investment activity among genome editing technology providers since 2018, evaluated by year, type of funding, amount invested, geography, and most active players and investors.
• Market Impact Analysis: An in-depth analysis of the drivers, restraints, opportunities, and challenges influencing the growth of the genome editing market.

Key Questions Answered in this Report

• How large is the genome editing market today, and how large will it be by 2035?
• Which gene editing techniques, delivery methods and delivery modalities are gaining or losing share?
• Which companies are best positioned across each segment, and how deep is their technology and pipeline portfolio?
• How is the balance between upfront and milestone-based licensing likely to evolve?
• Which application areas beyond drug discovery offer the strongest medium-term upside?
• Which geographies offer the best combination of near-term revenue and long-term growth rate?

Reasons to Buy this Report

Distributors evaluating the genome editing opportunity need more than a headline market size figure. This report is built to support commercial decision-making, not just awareness, and differentiates itself on the following counts:

• Top-Down and Bottom-Up Triangulated Forecasting: Revenue projections for each segment are cross-validated using both technology-adoption trends and company-level deal data, reducing forecast risk for investors and channel partners.
• Primary Research: Insights are grounded in interviews with CEOs, chief scientific officers, and business development leaders across large, mid-sized and academic organizations, not desk research alone.
• Investor-Grade Financial Context: Company profiles include funding history, recent capital deployment and partnership activity, positioned for use in diligence and business case development.
• Patent and IP Landscape Clarity: A dedicated patent benchmarking chapter helps distributors and licensees navigate the fragmented CRISPR intellectual property landscape before entering supply or distribution agreements.

Additional Benefits

• Complementary Insights Pack
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. BACKGROUND

• 1.1. Context
• 1.2. Project Objectives

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Values and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross Border Dynamics
• 4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

• 6.1. Chapter Overview
• 6.2. Introduction to Gene Editing
  • 6.2.1. Evolution of Gene Editing
  • 6.2.2. Gene Editing Technologies
    • 6.2.2.1. CRISPR - CAS System
    • 6.2.2.2. Transcription Activator-Like Effector Nucleases (TALENs)
    • 6.2.2.3. Zinc Finger Nucleases (ZFNs)
    • 6.2.2.4. Meganucleases / Homing Endonucleases
• 6.3. Applications of Genome Editing Technologies
• 6.4. Other Emerging Technologies
• 6.5. Concluding Remarks

7. MARKET LANDSCAPE: GENOME EDITING TECHNOLOGIES

• 7.1. Chapter Overview
• 7.2. Genome Editing: Technology Landscape
  • 7.2.1. Analysis by Type of Gene Editing Technique
  • 7.2.2. Analysis by Type of Gene Editing Approach
  • 7.2.3. Analysis by Type of Gene Delivery Method
  • 7.2.4. Analysis by Type of Gene Delivery Modality
  • 7.2.5. Analysis by Highest Phase of Drug Development Supported
  • 7.2.6. Analysis by Therapeutic Area
  • 7.2.7. Analysis by Application Area
• 7.3. Genome Editing: Technology Providers Landscape
  • 7.3.1. Analysis by Year of Establishment
  • 7.3.2. Analysis by Company Size
  • 7.3.3. Analysis by Location of Headquarters
  • 7.3.4. Analysis by Company Size and Location of Headquarters
  • 7.3.5. Most Active Players: Analysis by Number of Technologies
  • 7.3.6. Analysis by Operational Model

8. TECHNOLOGY COMPETITIVENESS ANALYSIS

• 8.1. Chapter Overview
• 8.2. Assumptions / Key Parameters
• 8.3. Methodology
• 8.4. Technology Competitiveness Analysis
  • 8.4.1. Genome Editing Technologies Offered by Players Headquartered in North America
  • 8.4.2. Genome Editing Technologies Offered by Players Headquartered in Europe
  • 8.4.3. Genome Editing Technologies Offered by Players Headquartered in Asia-Pacific, Middle East and North Africa, and Latin America

9. GENOME EDITING MARKET: COMPANY PROFILES OF PLAYERS BASED IN NORTH AMERICA

• 9.1. Chapter Overview
• 9.2. Arcturus Therapeutics
  • 9.2.1. Company Overview
  • 9.2.2. Financial Information
  • 9.2.3. Technology Portfolio
  • 9.2.4. Recent Developments and Future Outlook
• 9.3. Arsenal Bio
  • 9.3.1. Company Overview
  • 9.3.2. Technology Portfolio
  • 9.3.3. Recent Developments and Future Outlook
• 9.4. Beam Therapeutics
  • 9.4.1. Company Overview
  • 9.4.2. Financial Information
  • 9.4.3. Technology Portfolio
  • 9.4.4. Recent Developments and Future Outlook
• 9.5. Caribou Biosciences
  • 9.5.1. Company Overview
  • 9.5.2. Financial Information
  • 9.5.3. Technology Portfolio
  • 9.5.4. Recent Developments and Future Outlook
• 9.6. Century Therapeutics
  • 9.6.1. Company Overview
  • 9.6.2. Financial Information
  • 9.6.3. Technology Portfolio
  • 9.6.4. Recent Developments and Future Outlook
• 9.7. CRISPR Therapeutics
  • 9.7.1. Company Overview
  • 9.7.2. Financial Information
  • 9.7.3. Technology Portfolio
  • 9.7.4. Recent Developments and Future Outlook
• 9.8. Editas Medicine
  • 9.8.1. Company Overview
  • 9.8.2. Financial Information
  • 9.8.3. Technology Portfolio
  • 9.8.4. Recent Developments and Future Outlook
• 9.9. Intellia Therapeutics
  • 9.9.1. Company Overview
  • 9.9.2. Financial Information
  • 9.9.3. Technology Portfolio
  • 9.9.4. Recent Developments and Future Outlook
• 9.10. Prime Medicine
  • 9.10.1. Company Overview
  • 9.10.2. Technology Portfolio
  • 9.10.3. Recent Developments and Future Outlook
• 9.11. Vor Biopharma
  • 9.11.1. Company Overview
  • 9.11.2. Technology Portfolio
  • 9.11.3. Recent Developments and Future Outlook

10. GENOME EDITING MARKET: COMPANY PROFILES OF PLAYERS BASED IN EUROPE

• 10.1. Chapter Overview
• 10.2. Avectas
  • 10.2.1. Company Overview
  • 10.2.2. Technology Portfolio
• 10.3. Bio-Sourcing
  • 10.3.1. Company Overview
  • 10.3.2. Technology Portfolio
• 10.4. Flash Therapeutics
  • 10.4.1. Company Overview
  • 10.4.2. Technology Portfolio
• 10.5. NTrans Technologies
  • 10.5.1. Company Overview
  • 10.5.2. Technology Portfolio
• 10.6. OXGENE (Acquired by WuXi AppTec)
  • 10.6.1. Company Overview
  • 10.6.2. Technology Portfolio
• 10.7. Revvity (formerly known as Horizon Discovery)
  • 10.7.1. Company Overview
  • 10.7.2. Technology Portfolio

11. GENOME EDITING MARKET: COMPANY PROFILES OF PLAYERS BASED IN ASIA-PACIFIC AND REST OF THE WORLD

• 11.1. Chapter Overview
• 11.2. Edigene
  • 11.2.1. Company Overview
  • 11.2.2. Technology Portfolio
• 11.3. Fortgen
  • 11.3.1. Company Overview
  • 11.3.2. Technology Portfolio
• 11.4. G+FLAS Life Sciences
  • 11.4.1. Company Overview
  • 11.4.2. Technology Portfolio
• 11.5. TargetGene Biotechnologies
  • 11.5.1. Company Overview
  • 11.5.2. Technology Portfolio

12. PARTNERSHIPS AND COLLABORATIONS

• 12.1. Chapter Overview
• 12.2. Partnership Models
• 12.3. Genome Editing Technologies: Partnerships and Collaborations
  • 12.3.1. Analysis by Year of Partnership
  • 12.3.2. Analysis by Type of Partnership
  • 12.3.3. Analysis by Year and Type of Partnership
  • 12.3.4. Analysis by Purpose of Partnership
  • 12.3.5. Analysis by Type of Partner
  • 12.3.6. Analysis by Location of Headquarters of Partner
  • 12.3.7. Most Active Players: Analysis by Number of Partnerships
  • 12.3.8. Analysis by Geography
    • 12.3.8.1. Local and International Agreements
    • 12.3.8.2. Intercontinental and Intracontinental Agreements

13. PATENT ANALYSIS

• 13.1. Chapter Overview
• 13.2. Scope and Methodology
• 13.3. Genome Editing Domain: Patent Analysis
  • 13.3.1. Analysis by Publication Year
  • 13.3.2. Analysis by Type of Patent and Publication Year
  • 13.3.3. Analysis by Geography
  • 13.3.4. Analysis by CPC Symbols
  • 13.3.5. Leading Industry Players: Analysis by Number of Patents
• 13.4. Genome Editing Domain: Patent Benchmarking Analysis
  • 13.4.1. Analysis by Patent Characteristics
  • 13.4.2. Analysis by Leading Industry Players
• 13.5. Patent Valuation Analysis

14. FUNDING AND INVESTMENT ANALYSIS

• 14.1. Chapter Overview
• 14.2. Funding Models
• 14.3. Genome Editing Market: Funding and Investment Analysis
  • 14.3.1. Analysis by Year of Funding
    • 14.3.1.1. Cumulative Year-wise Trend of Funding Instances
    • 14.3.1.2. Cumulative Year-wise Trend of Amount Invested
  • 14.3.2. Analysis by Type of Funding
    • 14.3.2.1. Analysis by Funding Instances
    • 14.3.2.2. Analysis by Amount Invested
  • 14.3.3. Analysis by Year and Type of Funding
  • 14.3.4. Analysis by Geography
  • 14.3.5. Most Active Players: Analysis by Amount Invested and Number of Funding Instances
  • 14.3.6. Leading Investors: Analysis by Number of Funding Instances
• 14.4. Concluding Remarks

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 15.1. Chapter Overview
• 15.2. Market Drivers
• 15.3. Market Restraints
• 15.4. Market Opportunities
• 15.5. Market Challenges
• 15.6. Conclusion

16. GENOME EDITING TECHNOLOGIES MARKET

• 16.1. Chapter Overview
• 16.2. Assumptions and Methodology
• 16.3. Genome Editing Technologies Market: Forecasted Estimates, till 2035
  • 16.3.1. Scenario Analysis
    • 16.3.1.1. Conservative Scenario
    • 16.3.1.2. Optimistic Scenario
• 16.4. Key Market Segmentations

17. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. Genome Editing Technologies Market: Distribution by Type of Payment Method Employed
  • 17.3.1. Genome Editing Technologies Market for Milestone Payments: Forecasted Estimates, till 2035
  • 17.3.2. Genome Editing Technologies Market for Upfront Payments: Forecasted Estimates, till 2035
• 17.4. Data Triangulation

18. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF GENE EDITING TECHNIQUE

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Genome Editing Technologies Market: Distribution by Type of Gene Editing Technique
  • 18.3.1. Genome Editing Technologies Market for CRISPR-Cas System: Forecasted Estimates, till 2035
  • 18.3.2. Genome Editing Technologies Market for TALENs: Forecasted Estimates, till 2035
  • 18.3.3. Genome Editing Technologies Market for Meganucleases: Forecasted Estimates, till 2035
  • 18.3.4. Genome Editing Technologies Market for ZFNs: Forecasted Estimates, till 2035
  • 18.3.5. Genome Editing Technologies Market for Other Techniques: Forecasted Estimates, till 2035
• 18.4. Data Triangulation

19. GENOME EDITING TECHNOLOGIES MARKET, BY GENE EDITING APPROACH

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Genome Editing Technologies Market: Distribution by Gene Editing Approach
  • 19.3.1. Genome Editing Technologies Market for Gene Knock-Out Approaches: Forecasted Estimates, till 2035
  • 19.3.2. Genome Editing Technologies Market for Gene Knock-In Approaches: Forecasted Estimates, till 2035
• 19.4. Data Triangulation

20. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY METHOD

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Genome Editing Technologies Market: Distribution by Gene Delivery Method
  • 20.3.1. Genome Editing Technologies Market for Ex Vivo Delivery Methods: Forecasted Estimates, till 2035
  • 20.3.2. Genome Editing Technologies Market for In Vivo Delivery Methods: Forecasted Estimates, till 2035
• 20.4. Data Triangulation

21. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY MODALITY

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Genome Editing Technologies Market: Distribution by Gene Delivery Modality
  • 21.3.1. Genome Editing Technologies Market for Viral Vectors: Forecasted Estimates, till 2035
  • 21.3.2. Genome Editing Technologies Market for Non-Viral Vectors: Forecasted Estimates, till 2035
• 21.4. Data Triangulation

22. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF THERAPY

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Genome Editing Technologies Market: Distribution by Type of Therapy
  • 22.3.1. Genome Editing Technologies Market for Cell Therapies: Forecasted Estimates, till 2035
  • 22.3.2. Genome Editing Technologies Market for Gene Therapies: Forecasted Estimates, till 2035
  • 22.3.3. Genome Editing Technologies Market for Other Therapies: Forecasted Estimates, till 2035
• 22.4. Data Triangulation

23. GENOME EDITING TECHNOLOGIES MARKET, BY APPLICATION AREA

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. Genome Editing Technologies Market: Distribution by Application Area
  • 23.3.1. Genome Editing Technologies Market for Drug Discovery and Development: Forecasted Estimates, till 2035
  • 23.3.2. Genome Editing Technologies Market for Diagnostics: Forecasted Estimates, till 2035
• 23.4. Data Triangulation

24. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF END USER

• 24.1. Chapter Overview
• 24.2. Key Assumptions and Methodology
• 24.3. Genome Editing Technologies Market: Distribution by Type of End User
  • 24.3.1. Genome Editing Technologies Market for Pharmaceutical and Biotechnology Companies: Forecasted Estimates, till 2035
  • 24.3.2. Genome Editing Technologies Market for Academic and Research Institutes: Forecasted Estimates, till 2035
• 24.4. Data Triangulation

25. GENOME EDITING TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS

• 25.1. Chapter Overview
• 25.2. Key Assumptions and Methodology
• 25.3. Genome Editing Technologies Market: Distribution by Key Geographical Regions
  • 25.3.1. Genome Editing Technologies Market in North America: Forecasted Estimates, till 2035
    • 25.3.1.1. Genome Editing Technologies Market in the US: Forecasted Estimates, till 2035
    • 25.3.1.2. Genome Editing Technologies Market in Canada: Forecasted Estimates, till 2035
  • 25.3.2. Genome Editing Technologies Market in Europe: Forecasted Estimates, till 2035
    • 25.3.2.1. Genome Editing Technologies Market in Germany: Forecasted Estimates, till 2035
    • 25.3.2.2. Genome Editing Technologies Market in France: Forecasted Estimates, till 2035
    • 25.3.2.3. Genome Editing Technologies Market in Ireland: Forecasted Estimates, till 2035
  • 25.3.3. Genome Editing Technologies Market in Asia-Pacific: Forecasted Estimates, till 2035
    • 25.3.3.1. Genome Editing Technologies Market in South Korea: Forecasted Estimates, till 2035
    • 25.3.3.2. Genome Editing Technologies Market in China: Forecasted Estimates, till 2035
    • 25.3.3.3. Genome Editing Technologies Market in Japan: Forecasted Estimates, till 2035
• 25.4. Market Dynamics Assessment
  • 25.4.1. Penetration Growth (P-G) Matrix
• 25.5. Data Triangulation

26. GENOME EDITING TECHNOLOGIES MARKET: LEADING INDUSTRY PLAYERS

• 26.1. Chapter Overview
• 26.2. Leading Industry Players

27. CONCLUDING INSIGHTS

28. EXECUTIVE INSIGHTS

29. APPENDIX 1: TABULATED DATA

30. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS